EMCURE — Emcure Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapHigh Flyer

Annual income statement for Emcure Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	PROSPECTUS	PROSPECTUS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	60,564	58,554	59,858	66,583	78,960
Cost of Revenue
Gross Profit	34,296	35,250	36,167	40,628	47,494
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	52,363	47,699	50,706	57,509	68,216
Operating Profit	8,201	10,855	9,153	9,074	10,743
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	6,573	9,725	7,472	7,272	9,713
Provision for Income Taxes
Net Income After Taxes	4,186	7,026	5,618	5,276	7,075
Minority Interest
Net Income Before Extraordinary Items
Net Income	3,921	6,622	5,320	4,982	6,813
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	3,921	6,622	5,320	4,982	6,813
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	23.7	35	28.4	26.5	36.8
Dividends per Share